Amylyx Completes Enrollment for Key Phase 3 LUCIDITY Trial and Phase 1 LUMINA Cohort 2

summarizeSummary

Amylyx Pharmaceuticals announced the completion of enrollment for its Phase 3 LUCIDITY trial for avexitide and Phase 1 LUMINA trial Cohort 2, advancing its late-stage and early-stage clinical programs.

check_boxKey Events

• Phase 3 LUCIDITY Trial Enrollment Complete

  Enrollment for the pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia (PBH) has been completed, with topline data now expected in Q3 2026 and a potential commercial launch in 2027 if approved.

• Phase 1 LUMINA Trial Cohort 2 Enrollment Complete

  Enrollment for Cohort 2 of the Phase 1 LUMINA trial for AMX0114 in ALS has been completed. Early data from Cohort 1 showed AMX0114 was generally well-tolerated with no treatment-related serious adverse events.

• Updated Pipeline Progress

  The corporate presentation also highlighted positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome and the nomination of AMX0318 as a preclinical development candidate for PBH and other rare diseases.

• Extended Cash Runway

  The company reported a cash runway expected into 2028, with $317 million in cash, cash equivalents, and short-term investments as of December 31, 2025.

auto_awesomeAnalysis

Amylyx Pharmaceuticals announced significant progress across its clinical pipeline, notably completing enrollment for its pivotal Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia (PBH). This milestone de-risks the program and sets the stage for topline data in Q3 2026, with a potential commercial launch in 2027. Additionally, the company completed enrollment for Cohort 2 of its Phase 1 LUMINA trial for AMX0114 in ALS, further advancing its neurodegenerative disease pipeline. These updates, coupled with a strong cash runway into 2028, indicate solid operational execution and progress towards key clinical readouts.